Zheng Bin Yao
Chief Executive Officer chez ARRIVENT BIOPHARMA, INC.
Fortune : 11 M $ au 31/03/2024
Profil
Zheng Bin Yao is the founder of Arrivent BioPharma, Inc. founded in 2021, where he holds the title of Chairman & Chief Executive Officer.
He is currently an Independent Director at NexImmune, Inc. since 2017, a Director at Immune-Onc Therapeutics, Inc. since 2019, a Director at Alumis, Inc. since 2021, and an Independent Non-Executive Director at VISEN Pharmaceuticals since 2021.
Dr. Yao's former positions include Chairman, President & Chief Executive Officer at Viela Bio, Inc. from 2018 to 2021, SVP-Respiratory, Inflammation & Autoimmunity at MedImmune LLC from 2010 to 2018, Vice President-Research at Tanox, Inc. from 2000 to 2007, and Head-Immuno-Oncology Franchise at AstraZeneca PLC.
Dr. Yao holds a doctorate degree from the University of Iowa and a graduate degree from Anhui Medical University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC.
1,92% | 26/01/2024 | 613 138 ( 1,92% ) | 11 M $ | 31/03/2024 |
NEXIMMUNE, INC.
0,04% | 31/10/2023 | 505 ( 0,04% ) | 2 833 $ | 31/03/2024 |
Postes actifs de Zheng Bin Yao
| Sociétés | Poste | Début |
|---|---|---|
| NEXIMMUNE, INC. | Director/Board Member | 01/01/2017 |
| ARRIVENT BIOPHARMA, INC. | Chief Executive Officer | 01/06/2021 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Director/Board Member | 01/04/2019 |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Director/Board Member | 21/07/2021 |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Director/Board Member | 01/04/2021 |
Anciens postes connus de Zheng Bin Yao
| Sociétés | Poste | Fin |
|---|---|---|
| VIELA BIO, INC. | Chief Executive Officer | 15/03/2021 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Chief Tech/Sci/R&D Officer | 19/10/2007 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Formation de Zheng Bin Yao
| University of Iowa | Doctorate Degree |
| Anhui Medical University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| NEXIMMUNE, INC. | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Health Technology |
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
